Claims
- 1. A method for reducing intraocular pressure in a mammal, comprising administering to said mammal an effective amount of a compound having the formula:
- (HO).sub.p --A--[--OS(O).sub.2 NR.sup.1 R.sup.2 ].sub.z
- wherein
- A is aryloxy-alkyl, in which the aryl moiety is a substituted phenyl group of the formula: ##STR10## where X is hydrogen, halo, CF.sub.3, nitro-, --SO.sub.2 NR.sub.1 R.sub.2, loweralkoxy, hydroxy, amino, loweralkylamino, diloweralkylamino, methylcarbonylamino, loweralkyl, methyloxycarbonyl, 1H-imidazol-1-yl, 3-thiazole, 1-pyrrole, phenyl, 1H-triazol-1-yl, cyano, 2-loweralkyl-1H-imidazol-1-yl, 4-loweralkyl-1H-imidazol-1-yl, 4-phenyl-1H-imidazol-1-yl, --COOH, --COOM wherein M is a pharmaceutically acceptable metal cation, aryloxy or aroyl;
- Y is hydrogen, halo, loweralkoxy, hydroxy or loweralkyl; and
- W is hydrogen, loweralkoxy or loweralkyl;
- and said alkyl portion of A being substituted on one or more carbon atoms by the depicted sulfamyloxy group, where Z is the number of --OS(O).sub.2 NR.sup.1 R.sup.2 groups present on the alkyl moiety of A and is always at least one;
- p is the number of hydroxyl groups present on the alkyl moiety of A which have not been converted to --OS(O).sub.2 NR.sup.1 R.sup.2 groups, including zero;
- R.sup.1 is hydrogen or loweralkyl;
- R.sup.2 is hydrogen, loweralkyl, --CO.sub.2 R.sup.1, or --CO.sub.2 --M+ wherein M is defined above;
- and the pharmaceutically acceptable salts thereof when they can be formed and the optical isomers thereof, when they can be formed.
- 2. A method of claim 1 in which the compound having the formula:
- (HO).sub.p --A--[OS(O).sub.2 NH.sub.2 ].sub.z
- is water soluble and is administered topically to the eye of said mammal; and
- X is amino, loweralkylamino, diloweralkylamino, 1H-imidazol-1-yl, 2-loweralkyl-1H-imidazol-1-yl, 4-loweralkyl-1H-imidazol-1-yl, 1H-triazol-1-yl, COOH or COOM wherein M is a pharmaceutically acceptable cation;
- Y is hydrogen, halo, loweralkoxy, hydroxy or loweralkyl;
- W is hydrogen, loweralkoxy, or loweralkyl;
- and the pharmaceutically acceptable salts thereof when they can be formed and the optical isomers thereof when they can be formed.
- 3. The method of claim 1 wherein the compound used is sulfamic acid 1-[(2-methoxyphenoxy)methyl]-1,2-ethanediyl ester.
- 4. The method of claim 1 wherein the compound used is sulfamic acid 2-phenoxy-1,3-propanediyl ester.
- 5. The method of claim 1 wherein the compound used is sulfamic acid 2-(4-chlorophenoxy)ethyl ester.
- 6. The method of claim 1 wherein the compound used is methylsulfamic acid 2-(4-chlorophenoxy)ethyl ester.
- 7. The method of claim 1 wherein the compound used is methylsulfamic acid-3-phenoxy-1,2-propanediyl ester.
- 8. The method of claim 1 wherein the compound used is methylsulfamic acid 2-[4-(1H-imidazol-1-yl)phenoxy]ethyl ester, or a pharmaceutically acceptable salt thereof.
- 9. The method of claim 1 wherein the compound used is methylsulfamic acid 2-phenoxy-1,3-propanediyl ester.
- 10. The method of claim 1 wherein the compound used is sulfamic acid 2-[3-(1H-imidazol-1-yl)phenoxy]ethyl ester, or a pharmaceutically acceptable salt thereof.
- 11. The method of claim 1 wherein the compound used is sulfamic acid 2-[3-(2-methyl-1H-imidazol-1-yl)phenoxy]ethyl ester, or a pharmaceutically acceptable salt thereof.
- 12. The method of claim 1 wherein the compound used is sulfamic acid 2-[3-(diethylamino)phenoxy]ethyl ester, or a pharmaceutically acceptable salt thereof.
- 13. The method of claim 1 wherein the compound used is sulfamic acid 2-(4-chlorophenoxy)-1,3-propanediyl ester.
- 14. The method of claim 1 wherein the compound used is methylsulfamic acid 2-(4-chlorophenoxy)-1,3-propanediyl ester.
- 15. The method of claim 1 wherein the compound used is sulfamic acid 2-[4-(1H-imidazol-1-yl)phenoxy]ethyl ester, or a pharmaceutically acceptable salt thereof.
- 16. The method of claim 1 wherein the compound used is dimethyl sulfamic acid 2-[4-(1H-imidazol-1-yl)phenoxy]ethyl ester, or a pharmaceutically acceptable salt thereof.
- 17. A pharmaceutical composition for lowering intraocular pressure in a mammal comprising an effective amount of a compound of the formula:
- (HO).sub.p --A--[--OS(O).sub.2 NR.sup.1 R.sup.2 ].sub.z
- wherein
- A is aryloxy-alkyl, in which the aryl moiety is a substituted phenyl group of the formula: ##STR11## where X is hydrogen, halo, CF.sub.3, nitro-, --SO.sub.2 NR.sub.1 R.sub.2, loweralkoxy, hydroxy, amino, loweralkylamino, diloweralkylamino, methylcarbonylamino, loweralkyl, methyloxycarbonyl, 1H-imidazol-1-yl, 3-thiazole, 1-pyrrole, phenyl, 1H-triazol-1-yl, cyano, 2-loweralkyl-1H-imidazol-1-yl, 4-loweralkyl-1H-imidazol-1-yl, 4-phenyl-1H-imidazol-1-yl, --COOH, --COOM wherein M is a pharmaceutically acceptable metal cation, aryloxy or aroyl;
- Y is hydrogen, halo, loweralkoxy, hydroxy or loweralkyl; and
- W is hydrogen, loweralkoxy or loweralkyl; and said alkyl portion of A being substituted on one or more carbon atoms by the
- depicted sulfamyloxy group, where Z is the number of --OS(O).sub.2 NR.sup.1 R.sup.2 groups present on the alkyl moiety of A and is always at least one;
- p is the number of hydroxyl groups present of the alkyl moiety of A which have not been converted to --OS(O).sub.2 NR.sup.1 R.sup.2 groups, including zero;
- R.sup.1 is hydrogen or loweralkyl;
- R.sup.2 is hydrogen, loweralkyl, --CO.sub.2 R.sup.1, or --CO.sub.2 M+wherein M is defined above;
- and the pharmaceutically acceptable salts thereof when they can be formed and the optical isomers thereof, when they can be formed, and a pharmaceutically acceptable carrier.
- 18. A pharmaceutical composition for topical administration to the eye of a mammal in need thereof comprising an effective amount of a water soluble compound having the formula:
- (HO).sub.p --[OSO.sub.2 NH.sub.2 ].sub.2
- wherein:
- A is aryloxy-alkyl in which the aryl moiety is a substituted phenyl group of the formula: ##STR12## wherein X is amino, loweralkylamino, diloweralkylamino, 1H-imidazol-1-yl, 4-loweralkyl-1H-imidazol-1-yl, 1H-triazol-1-yl, --COOH or --COOM wherein M is a pharmaceutically acceptable cation;
- Y is hydrogen, halo, loweralkoxy, hydroxy or loweralkyl;
- W is hydrogen, loweralkoxy or loweralkyl; and said alkyl portion of A being substituted on one or more carbon atoms by the depicted sulfamoyloxy group, where Z is the number of --OS(O).sub.2 NH.sub.2 groups present and is always at least one;
- p is the number of hydroxygroups present on the alkyl moiety of A which have not been converted to --OS(O).sub.2 NH.sub.2 groups, including zero;
- or a pharmaceutically acceptable salt thereof when they can be formed; the optical isomers thereof when they can be formed; and a pharmaceutically acceptable carrier.
- 19. A pharmaceutical composition comprised of a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound which is a pharmaceutically acceptable salt of sulfamic acid 2-[4(1H-imidazol-1-yl)phenoxy]ethyl ester.
- 20. A pharmaceutical composition comprised of a pharmaceutically acceptable carrier and a therapeutically effective amount of methylsulfamic acid 1-[(2-methoxyphenoxy)-methyl]-1,2-ethanediyl ester.
Parent Case Info
This application is a continuation-in-part of pending application Ser. No. 07/406,736 filed Sep. 3, 1989, now abandoned.
US Referenced Citations (5)
Non-Patent Literature Citations (2)
Entry |
Weiss Liebigs Ann Chem 729 40 (1969). |
Maryanoff, et al. J. Med. Chem. 1987, 30, 880-887. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
406736 |
Sep 1989 |
|